Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief ...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...

If you are wondering whether Eisai is quietly becoming a value opportunity or just a value trap, you are in the right place to unpack what the current share price is really implying. The stock has ...

Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...

Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...

Eisai and partner BioArctic recently reported at the CTAD 2025 conference that long-term data for Leqembi (lecanemab) suggest early, continued treatment can substantially delay progression from mild ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and ...

(RTTNews) - Eisai Co., Ltd. and Biogen Inc. announced new findings on the continued and expanding benefit of LEQEMBI (lecanemab-irmb) maintenance treatment in early Alzheimer's disease at the 18th ...

Eisai Presents New Data On The Continued And Expanding Benefit Of LEQEMBI(R) (Lecanemab-Irmb) Maintenance Treatment In Early Alzheimer's Disease At CTAD 2025. Eisai Presents New Data on the Continued ...

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s diseaseby up to 8.3 years in low-amyloid group who started ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...